Takeda Canada Inc. (Takeda) is pleased to announce that Health Canada has expanded the marketing authorization for HyQvia® ...

In conclusion, we consider that the available data indicate that IVIg is not a lost cause for the therapy of MS 15,16, and that clinical trials are therefore warranted to determine if a ...

Intravenous immunoglobulin (IVIG) is a type of medication used to treat people with immunodeficiencies, when the immune ...

Recent human trials of a new one-year-long immune-based treatment for post-polio syndrome, which can strike polio survivors ...

Patients who are getting immune globulin for the first time ... This medication is made from human blood. Even though the blood is carefully tested, and this medication goes through a special ...

Spanish plasma-derived medicines specialist Grifols (MCE: GRF) has announced positive results from its Phase II/III clinical ...

Topline data were announced from a phase 2/3 trial evaluating Flebogamma 5% DIF (immune globulin intravenous ) in patients with post-polio syndrome (PPS).